Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Beth A. Warren"'
Autor:
Beth B. Warren
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 7, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/af17f59a520f4165a82dc1b60234b7ce
Autor:
Beth Boulden Warren, Adrian Chan, Marilyn Manco‐Johnson, Brian R. Branchford, Tyler W. Buckner, Genevieve Moyer, Elizabeth Gibson, Dianne Thornhill, Michael Wang, Christopher J Ng
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Abstract Background Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products. Objective To better understand the early impact of emiciz
Externí odkaz:
https://doaj.org/article/843509569c104acf9c878312de8b64d7
Autor:
Vanessa R. Byams, Judith R. Baker, Cindy Bailey, Nathan T. Connell, Melissa S. Creary, Randall G. Curtis, Alexis Dinno, Christine J. Guelcher, Michelle Kim, Roshni Kulkarni, Susan Lattimore, Keri L. Norris, Lucy Ramirez, Mark W. Skinner, Susan Symington, Patricia Tobase, Esmeralda Vázquez, Beth B. Warren, Emily Wheat, Tyler W. Buckner
Publikováno v:
Expert Review of Hematology. 16:87-106
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e223d126421151cb4cd2a69227393f90
https://doi.org/10.1080/17474086.2023.2183836
https://doi.org/10.1080/17474086.2023.2183836
Publikováno v:
Seminars in Thrombosis and Hemostasis. 49:319-329
The hemostasis system is composed of procoagulant, anticoagulant, and fibrinolytic proteins that interact with endothelial and blood cells and with each other in a complex system of checks and balances to maintain blood flow while preventing both hem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::945681ed5dba1df4b87dacbcc91ad3ff
https://doi.org/10.1055/s-0042-1760332
https://doi.org/10.1055/s-0042-1760332
Publikováno v:
Hematology Am Soc Hematol Educ Program
Currently, we are at an enviable place in hemophilia treatment. Although full prophylaxis with standard half-life recombinant or plasma-derived factor concentrates has been definitively shown to be inadequate for full protection against bleeding and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1ca88ab52005dddc61c958a5a63177f
https://pubmed.ncbi.nlm.nih.gov/36485126
https://pubmed.ncbi.nlm.nih.gov/36485126
Autor:
Neil A. Goldenberg, Rhonda Knapp-Clevenger, Marilyn J. Manco-Johnson, Lillian Sung, Julie Smith, Beth Boulden Warren, Dianne Thornhill, Susan R. Kahn, Leonardo R. Brandão
Publikováno v:
Thrombosis and Haemostasis. 121:1367-1375
Background There is need for validated outcome measures for postthrombotic syndrome (PTS) following pediatric venous thromboembolism (VTE), with a focus on quality of life (QoL). Aims This article assesses reliability and validity of two PTS and two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650ec2d39d2adb0ecf2b9f8d5ffd1539
https://doi.org/10.1055/s-0041-1725199
https://doi.org/10.1055/s-0041-1725199
Publikováno v:
Haemophilia. 27:87-95
Options for management of haemophilia are increasing rapidly with completely novel therapeutic approaches that cannot be compared using traditional factor assays. In addition, as prophylaxis regimens have improved, bleeding rates have decreased, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c205a11603744f0cf4ded08735618c07
https://doi.org/10.1111/hae.14099
https://doi.org/10.1111/hae.14099
Autor:
Heidi Lane, Kristi L. Norton, Amy L. Dunn, Beth Boulden Warren, Carolyn M. Bennett, Michael Fadell, Sharon Funk, Marilyn J. Manco-Johnson, J. David Ingram, Dianne Thornhill, Amy D. Shapiro, Michael Recht, Jill Stein
Publikováno v:
Blood Adv
The Joint Outcome Study (JOS), a randomized controlled trial, demonstrated that children with severe hemophilia A (HA) initiating prophylactic factor VIII (FVIII) prior to age 2.5 years had reduced joint damage at age 6 years compared with those trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a65db6e88ff8f3367f78ac13a937e1
https://doi.org/10.1182/bloodadvances.2019001311
https://doi.org/10.1182/bloodadvances.2019001311
Autor:
Beth Boulden Warren, Stephen C. Elliott, Katherine M. Bellone, Linda S. Hynan, Robin B. Jarrett
Publikováno v:
Journal of Autism and Developmental Disorders
We conducted an open-trial proof of concept study to determine the safety, acceptability, and feasibility of Mindful Self-Care for Caregivers (MSCC) for parents of children with Autism Spectrum Disorders (ASD) (N = 13). The intervention was offered a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bcd99e7501183bb86d8f9e080dcde71
https://pubmed.ncbi.nlm.nih.gov/34109461
https://pubmed.ncbi.nlm.nih.gov/34109461
Autor:
Michael Wang, Adrian Chan, Beth Boulden Warren, Brian R. Branchford, Tyler W. Buckner, Christopher J. Ng, Genevieve Moyer, Elizabeth Gibson, Dianne Thornhill, Marilyn J. Manco-Johnson
Publikováno v:
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Background Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products. Objective To better understand the early impact of emicizumab on o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a57f87e5ca44b2a9cd088ce8eaf4474b
https://pubmed.ncbi.nlm.nih.gov/34377887
https://pubmed.ncbi.nlm.nih.gov/34377887